肺动脉高压市场战略、顶级参与者、增长机会、2028 年分析和预测

  • Report Code : TIPRE00005221
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 174
Buy Now

Pulmonary Arterial Hypertension Market Size and Share by 2028

Buy Now

 

肺动脉高压市场预计将从 2021 年的 73.6989 亿美元增长到 2028 年的 108.8908 亿美元;预计 2022 年至 2028 年的复合年增长率为 5.8%。

肺动脉高压市场根据药物、类型、给药途径、分销渠道和地理位置进行细分。该报告提供了对肺动脉高压市场的见解和深入分析,强调了各种参数,例如市场动态、趋势和机会以及各地区主要市场参与者的竞争格局分析。它还包括 COVID-19 大流行对各地区肺动脉高压市场的影响分析。

 

定制研究以满足您的需求

我们可以优化和定制标准产品无法满足的分析和范围。这种灵活性将帮助您获得业务规划和决策所需的准确信息。

肺动脉高压市场:

肺动脉高压市场
  • Pulmonary Arterial Hypertension Market
    复合年增长率(2021 - 2028 年)
    5.8%
  • 2021 年市场规模
    73.7 亿美元
  • 2028 年市场规模
    108.9 亿美元

市场动态

增长动力
  • 財政部
  • 財政部
  • 財政部
未来的趋势
  • 財政部
  • 財政部
  • 財政部
机会
  • 財政部
  • 財政部
  • 財政部

关键人物;主力;重要一员

  •  
  • 强生公司
  • 吉利德科学公司
  • 联合治疗公司
  • 拜耳公司
  • Aerami Therapeutics Holdings Inc
  • 诺华公司
  • 葛兰素史克公司
  • 梯瓦制药工业有限公司
  • 鲁宾有限公司

区域概况

Pulmonary Arterial Hypertension Market
  • 北美
  • 欧洲
  • 亚太
  • 南美洲和中美洲
  • 中东和非洲

市场细分

Pulmonary Arterial Hypertension Market药物
  • 内皮素受体拮抗剂
Pulmonary Arterial Hypertension Market类型
  • 品牌药和仿制药
Pulmonary Arterial Hypertension Market给药途径
  • 口服
  • 静脉/皮下
  • 吸入
Pulmonary Arterial Hypertension Market分销渠道
  • 医院药房和诊所
  • 网上药店
  • 零售药店
  • 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。

 

市场洞察

 

肺动脉高压药物获批数量增加推动市场增长

  • 2022 年 9 月,东丽株式会社获得中国国家药品监督管理局 (NMPA) 批准,可生产用于治疗肺动脉高压 (PAH) 的 Careload 片剂。Careload 是一种口服缓释制剂,其成分为贝前列素钠,是一种前列环素衍生物 (PGI2)。
  • 2022年5月,联合治疗公司获得美国食品药品监督管理局(FDA)批准Tyvaso DPI(曲前列尼尔)吸入粉剂用于治疗间质性肺病相关肺动脉高压(PH-ILD;WHO Group 3)和肺动脉高压(PAH;WHO Group 1),以增强运动能力。
  • 2021年11月,美国FDA临时批准Yutrepia(曲前列尼尔)吸入粉剂。Yutrepia适用于治疗PAH,以改善纽约心脏协会(NYHA)功能分级II-III级症状的成年患者的运动能力。
  • 2021 年 7 月,强生旗下杨森制药公司获得 FDA 批准,可使用 UPTRAVI(司来帕格)注射液进行静脉(IV)治疗 PAH;适用于 WHO 功能分级 (FC) II–III 的 WHO I 级成年患者,这些患者暂时无法接受口服治疗。
  • 2021 年 8 月,Aerami Therapeutics, Inc. 宣布,FDA 授予该公司伊马替尼孤儿药资格,用于治疗 PAH 患者。AER- 901 是一种用于治疗 PAH 的吸入伊马替尼药物-器械组合候选产品,目前正处于 1 期试验阶段,预计于 2021 年底完成。

全球范围内批准的肺动脉高压药物不断增多,推动了肺动脉高压市场的增长。

 

基于药物的见解

根据药物,肺动脉高压市场细分为内皮素受体拮抗剂 (ERA)、前列环素和前列环素类似物、sGC 刺激剂和 pde-5 试纸。前列环素和前列环素类似物部分在 2021 年占据最大市场份额,预计在 2022-2028 年期间将实现最高复合年增长率。前列环素是一种小脂质二十烷酸分子,也称为前列腺素 I-2 (PGI-2),由内皮细胞产生并局部作用,抑制血小板活化并引起血管舒张。前列环素扩张血管,通过防止血管平滑肌细胞增殖来改善血流,并通过抑制血小板聚集来防止血液凝固。前列环素类似物已被开发为 PAH 的治疗方法。PAH 前列环素类似物是前列环素的合成形式,前列环素是体内产生的天然物质。患有肺动脉高压 (PAH) 的患者往往前列环素水平降低,导致血管收缩和高血压。PAH 前列环素类似物可补充需求并模仿天然前列环素的作用,以降低肺动脉高压并减轻相关症状。

 

基于类型的洞察

 

根据类型,肺动脉高压市场分为品牌药和仿制药。品牌药部分在 2021 年占据了更大的市场份额,预计在预测期内将实现更高的复合年增长率。一家制药公司以特定名称或商标销售受专利保护的品牌药。品牌药可以通过处方或非处方获得。利奥西呱以 Adempas 品牌名称出售,是拜耳的可溶性鸟苷酸环化酶药物刺激剂。它用于治疗两种形式的肺动脉高压——慢性血栓栓塞性肺动脉高压和肺动脉高压。

 

基于给药途径的见解

根据给药途径,肺动脉高压市场细分为口服、静脉/皮下和吸入。口服部分在 2021 年占据了最大的市场份额,预计在预测期内将实现最高的复合年增长率。用于治疗有症状的中度至重度 PAH 的口服药物包括西地那非和内皮素 (ET) 受体拮抗剂 (ERA)、波生坦和西他生坦 (sitaxsentan),以及阿布生坦口服 ET(A) 受体选择性 ERA,其 ET 受体亲和力高于波生坦。此外,用于治疗 PAH 的新型口服药物包括马西替坦、利奥西呱和曲前列尼尔。安立生坦是一种内皮素受体拮抗剂,用于治疗 PAH;WHO 第 1 组并延缓临床恶化。安立生坦与他达拉非联合使用,可以降低病情进展和因肺动脉高压恶化而住院的风险,并改善运动能力。

 

基于分销渠道的洞察

根据分销渠道,肺动脉高压市场细分为医院药房和诊所、在线药房和零售药房。医院药房和诊所部分在 2021 年占据了最大的市场份额,预计在预测期内将实现最高的复合年增长率。医院药房致力于在医院环境中不断保持和改善患者的药物管理和药物护理,以达到最高标准。该领域的药剂师负责配药、质量测试、配制和重新配制剂型、监测、报告药物安全以及编制药物预算。

肺动脉高压市场参与者采用产品发布和扩张等有机策略,以扩大其在全球的足迹和产品组合并满足不断增长的需求。市场上见证的无机增长战略是合作伙伴关系和协作。这些增长战略使市场参与者能够扩大业务并增强其地理影响力。此外,收购、合作伙伴关系和其他增长战略有助于加强公司的客户群并增加其产品组合。

  • 2022年9月,鲁宾公司在美国FDA批准下在美国市场推出了西地那非口服混悬剂。该药是Viatris Specialty LLC公司Revatio口服混悬剂的仿制药。西地那非口服混悬剂用于治疗肺动脉高压。
  • 2021 年 2 月,Aerami Therapeutics, Inc. 与杭州 Chance Pharmaceuticals Co. Ltd.(Chance)签署了独家许可和开发协议,以在中国大陆、香港、澳门和台湾开发和商业化 Aerami 的药物-设备组合候选产品(“AER-901”),用于治疗 PAH。根据该协议,Chance 负责该地区用于 PAH 的 AER-901 的全面开发和商业化。

 

肺动脉高压市场报告范围

报告属性细节
2021 年市场规模73.7 亿美元
2028 年市场规模108.9亿美元
全球复合年增长率(2021 - 2028)5.8%
历史数据2019-2020
预测期2022-2028
涵盖的领域通过药物
  • 内皮素受体拮抗剂
按类型
  • 品牌药和仿制药
按给药途径
  • 口服
  • 静脉/皮下
  • 吸入
按分销渠道
  • 医院药房和诊所
  • 网上药店
  • 零售药店
覆盖地区和国家北美
  • 我们
  • 加拿大
  • 墨西哥
欧洲
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 意大利
  • 欧洲其他地区
亚太
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
南美洲和中美洲
  • 巴西
  • 阿根廷
  • 南美洲和中美洲其他地区
中东和非洲
  • 南非
  • 沙特阿拉伯
  • 阿联酋
  • 中东和非洲其他地区
市场领导者和主要公司简介
  •  
  • 强生公司
  • 吉利德科学公司
  • 联合治疗公司
  • 拜耳公司
  • Aerami Therapeutics Holdings Inc
  • 诺华公司
  • 葛兰素史克公司
  • 梯瓦制药工业有限公司
  • 鲁宾有限公司
  • 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。

 

公司简介

  • 强生公司                   
  • 吉利德科学公司                  
  • 联合治疗公司          
  • 拜耳公司
  • Aerami Therapeutics Holdings Inc                                                       
  • 诺华公司                            
  • 葛兰素史克公司                                                                               
  • 鲁宾有限公司                                
  • 辉瑞公司
  • 梯瓦制药工业有限公司
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Which region is dominating the pulmonary arterial hypertension market?

The global pulmonary arterial hypertension based on regions is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. In 2021, North America held the largest market share. However, the Asia Pacific region is estimated to grow at the fastest CAGR of 6.5% during the forecast period.

Which segment is dominating the pulmonary arterial hypertension market?

Based on drugs, the pulmonary arterial hypertension market is segmented into prostacyclin and prostacyclin analogs, endothelin receptor antagonists (ERAs), sGC stimulators, and pde-5 dipsticks. In 2021, the prostacyclin and prostacyclin analogs segment accounted for a larger market share. Also, the same segment is anticipated to register a higher CAGR during the forecast period as the PAH prostacyclin analogs are used as medications to treat pulmonary arterial hypertension (PAH), a condition of high blood pressure in the arteries that carry deoxygenated blood from the heart to the lungs.

Who are the major players in pulmonary arterial hypertension across the globe?

Pulmonary arterial hypertension majorly consists of the players, such as Johnson & Johnson, Gilead Sciences Inc, United Therapeutics Corp, Bayer AG, Aerami Therapeutics Holdings Inc, Novartis AG, GSK Plc, Teva Pharmaceutical Industries Ltd, Lupin Ltd, and Pfizer Inc.

What are the driving factors for global pulmonary arterial hypertension worldwide?

The factors driving the growth of pulmonary arterial hypertension are the growing incidence of pulmonary arterial hypertension and the rising approvals of pulmonary arterial hypertension drugs.

What are the restraining factors for global pulmonary arterial hypertension worldwide?

The side effects of drugs used for treating pulmonary arterial hypertension are expected to restrict the pulmonary arterial hypertension market growth during the forecast period.

What is pulmonary arterial hypertension?

Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by high blood pressure (hypertension) in the lungs' arteries. The increased pressure in the vessels may be caused by an obstruction in the lung's small arteries for various reasons. The exact cause of PAH is unknown, and although treatable, there is no permanent cure for the disease. PAH usually affects women between the ages of 30-60. However, individuals with PAH may go years without a diagnosis, either because the symptoms may be mild, nonspecific, or only present during demanding exercise.

The List of Companies - Butterfly Needles Market

  1. Johnson & Johnson
  2. Gilead Sciences Inc
  3. United Therapeutics Corp
  4. Bayer AG
  5. Aerami Therapeutics Holdings Inc
  6. Novartis AG
  7. GSK Plc
  8. Teva Pharmaceutical Industries Ltd
  9. Lupin Ltd
  10. Pfizer Inc

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Pharmaceuticals : READ MORE..